Investors of Alexion Pharmaceuticals (ALXN) have voted in favor of the company’s acquisition by AstraZeneca. Pending regulatory approvals, the transaction is expected to close in...
By Pushkala Aripaka and Ludwig Burger (Reuters) -AstraZeneca said a "meaningful proportion" of its shareholders voted against CEO Pascal Soriot's improved pay package on Tuesday,...
The biotech sector continues to be in focus with pipeline and regulatory updates. Earnings updates from Regeneron (NASDAQ:REGN) REGN and Moderna (NASDAQ:MRNA) MRNA also grab the...
The biotech sector continues to be in focus as the development of vaccines for coronavirus continues to be the key focus. Other pipeline and regulatory updates also grabbed the...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 315.94 | 316.85 | 309.08 | +10.68 | +3.50% | 19.04M | NASDAQ | |||
| 2,278.38 | 2,284.72 | 2,250.00 | +49.34 | +2.21% | 1.56M | NASDAQ | |||
| 42.17 | 43.09 | 41.22 | +1.27 | +3.11% | 2.25M | NASDAQ | |||
| 12.98 | 14.34 | 12.57 | +0.21 | +1.64% | 206.19M | NYSE | |||
| 159.92 | 166.47 | 156.22 | -4.58 | -2.78% | 4.27M | NYSE | |||
| 209.51 | 210.94 | 206.02 | +3.43 | +1.66% | 30.99M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 16.00 | 16.10 | 15.71 | +0.60 | +3.93% | 3.40M | NYSE | |||
| 7.78 | 7.79 | 7.58 | +0.28 | +3.73% | 13.79M | NYSE | |||
| 0.8047 | 0.00 | 0.00 | +0.0287 | +3.70% | 1.69M | NYSE | |||
| 1.14 | 1.15 | 1.06 | +0.1000 | +9.62% | 8.47M | NYSE | |||
| 70.02 | 70.27 | 69.28 | +1.14 | +1.66% | 783.45K | NYSE | |||
| 258.37 | 280.64 | 256.35 | -6.73 | -2.54% | 11.67M | NASDAQ | |||
| 58.69 | 59.26 | 58.67 | -0.12 | -0.20% | 13.70M | NYSE | |||
| 112.46 | 112.83 | 110.24 | +3.71 | +3.41% | 8.26M | NYSE |
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.